The USAID program is offering a grant to support the introduction of microbicides for HIV prevention in developing countries. After the success of the CAPRISA 004 clinical trial with 1% tenofovir gel, there is a need to confirm safety, effectiveness, and obtain regulatory approval for this new prevention technology. This grant aims to advance the USAID program towards the introduction of microbicides, focusing on improving and developing new products for HIV prevention. Proposals should address activities that contribute to the introduction and distribution of microbicides. Closing date for submissions is March 18, 2013.
Opportunity ID: 218854
General Information
| Document Type:: | Grants Notice |
| Funding Opportunity Number:: | APS-OAA-13-000001 |
| Funding Opportunity Title:: | APS for Microbicide Research, Development, and Introduction, Round 2 |
| Opportunity Category:: | Discretionary |
| Opportunity Category Explanation:: | |
| Funding Instrument Type:: | |
| Category of Funding Activity:: | Health |
| Category Explanation:: | |
| Expected Number of Awards:: | |
| Assistance Listings Number(s):: | 98.001 — USAID Foreign Assistance for Programs Overseas |
| Cost Sharing or Matching Requirement:: | Yes |
| Version:: | Synopsis 1 |
| Posted Date:: | Feb 04, 2013 |
| Last Updated Date:: | |
| Original Closing Date for Applications:: | Mar 18, 2013 |
| Current Closing Date for Applications:: | Mar 18, 2013 |
| Archive Date:: | Apr 17, 2013 |
| Estimated Total Program Funding:: | |
| Award Ceiling:: | $168,000,000 |
| Award Floor:: | $0 |
Eligibility
| Eligible Applicants:: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility:: |
Additional Information
| Agency Name:: | Agency for International Development |
| Description:: | The CAPRISA 004 clinical trial of 1% tenofovir gel, conducted by South African investigators and jointly supported by USAID and the Government of South Africa, was the first demonstration that a vaginal microbicide could significantly reduce the risk of HIV infection. This proof of concept, announced in July 2010, focused attention on the need to confirm the safety and effectiveness of this product, obtain regulatory approval from the relevant national authorities, and prepare for introduction of this new HIV prevention technology designed to help meet the needs of women in developing countries. Simultaneously, other promising microbicide leads are moving forward in the product development pipeline as well. Although research and development (R&D) for improved and alternative microbicide products will continue to be of interest, a new and broader range of activities is now needed to move the USAID program forward toward microbicide introduction. |
| Link to Additional Information:: | |
| Grantor Contact Information:: | If you have difficulty accessing the full announcement electronically, please contact: |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Synopsis 1 |
Package Status
Package No: 1